Cadrenal Therapeutics, Inc. cotiza a 1.01 USD y tiene una capitalización bursátil de $4M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths …
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-1.04 | $-1.41 | $-1.31 | $-1.87 |
| Estimado | $-1.57 | $-1.21 | $-1.55 | $-1.77 |
| Sorpresa | +33.8% | -16.5% | +15.5% | -5.6% |
| Métrica | CVKD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -483.3% | -40.4% | -442.9% |
| ROA | -305.9% | -32.0% | -273.9% |
| Current Ratio | 2.72 | 2.84 | -0.12 |
| Debt / Equity | — | 0.28 | — |